In the New Medicines for Trypanosomatidic Infections (NMTRypI) project funded by the EU, we have discovered novel anti-leishmania and anti-trypanosoma hits that inhibit pteridine reductase 1 (PTR1). Here, we synthesized compounds with a flavanone scaffold and characterized their antiparasitic activity and ADME-tox properties. Crystal structure determination and computational docking explain differences in their inhibition of PTR1. Two crystal structures of one compound with different PTR1 enzymes provide a basis for further scaffold optimization to develop inhibitors targeting PTR1 enzymes from different parasites. Molecules 2017, 22(3), 426; doi: 10.3390/molecules22030426
Results in brief from Cordis citations http://cordis.europa.eu/project/rcn/109924_en.html.
A special citation of the EU Commission for the results achieved within the project New Medicine for Trypanosomatidic infections. Grant Number: 603240.
Invitation by the EU Commission: The EU Commission Invited the Coordinators of the FP7 projects to present the project results at the following meeting: Satellite Symposium on Neglected Infectious Diseases during the ECTMIH 2017. The session will most probably take place on the 19th October in Antwerp.